leisure time -WSS

leisure time

author：entertainment 2025-10-01 14:17:19 - browse：84775

Truvian Health employee with a plate holding reagents used to measure commonly tested blood markers. Truvian

SAN DIEGO — Truvian Health, a San Diego blood diagnostics company, shared data on Tuesday showing that its benchtop instrument’s results are largely consistent with those generated by large central laboratories. But while the results lend support for the company’s vision of decentralized and widely available clinical testing, they also resurface questions about the value of an approach widely associated with the now defunct and notorious Bay Area startup Theranos.

In a multisite study, the company tested nearly 240 blood samples from healthy donors and chronic disease patients for dozens of blood-based measurements commonly ordered by doctors, from cholesterol to blood sugar to blood cell counts. Results from Truvian’s benchtop analytical instrument, with few exceptions, closely matched readings from devices used in large central labs and made by Swiss pharma giant Roche and Japanese firm Sysmex.

The findings were presented at the annual meeting of the American Association for Clinical Chemistry, recently rebranded as the Association for Diagnostics & Laboratory Medicine. It’s the first time Truvian has shared clinical data on its product, though they have not been published in a peer-reviewed journal. The company, which is planning additional validation studies, expects to submit for Food and Drug Administration approval of its device by the third quarter of 2024.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Dog Aging Project founders on what lies ahead after losing funding

explore

WSS

FDA sets aggressive timeline for overhauling inspection procedures

Dana Farber says 6 studies to be retracted and 31 corrected

Pumping milk in bathrooms at health conferences is common

Medicare reduced heart disease by changing how it pays doctors

First Opinion Podcast: Long Covid needs a new approach

Head of FDA's diagnostics center, who led through Covid, retires

explore

leisure time

focus

Continuity nursing helped my family in our darkest PICU moments

FDA gives detailed accounting of AI

The cancer drug shortage isn’t new — and neither are the solutions

FDA endorses new sterilization method for medical devices

How to save PrEP access — and even expand it

FDA gives detailed accounting of AI

Supreme Court strikes down use of affirmative action

CEOs share strategies for surviving biotech slump

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

2023 STAT Wunderkinds: get to know the winners

focus

The inclusion problem at the heart of rehabilitation research

Inaction leaves children at risk from dangerous chemotherapy drug

Maisha Meds is a PBM, but don't call it that

TikTok, Instagram influencers need more rules for drug ads

FDA struggles to regulate food additives, sometimes for decades

2023 STAT Wunderkinds: get to know the winners

entertainment

explore

explore

hotspot